thank call and ir.navidea.com for us joining a Thank being you webcast This available. made is will website, live today. replay you be all on and our
of conducting remarks, prepared Q&A Vice Erika on joining we will be the Finance Following a call Administration, and today. will session. live Navidea’s be me Eves President
These our the will statements regarding forward-looking plans the of future of Navidea’s During performance making molecular course to this be conference events the develop to company. clinical immunotherapeutics, which resources regulatory and well events the operations. business call, of timing clinical and relate matters we on strategic readouts, diagnostics include as capital and with pandemic developments impact of business COVID-XX and along the as data Navidea’s and future
beliefs to statements of revise included recent new obligation We uncertainties certain assumptions, filings to result All are and should the expectations the as carefully as a Investors of These could the and differ forward-looking or results uncertainties update on based cause statements and today. these actual read materially. events as risks involve statements section as risk whether management otherwise. no most annual SEC. our of or risks well the factors future Safe assume company’s website within the of quarterly the described and information, Harbor in with of and
let’s our with update. that, begin with So
continued financing to During the on fourth XXXX quarter work of have the we company. since, for and
senior on the Board I We be that time, say Directors current options being and at but have are pursued. This engaged with can management is this all investment an and working bank assured tirelessly. are of the
progress Overall, made imaging Phase to as Xb dialogue with able X our we you rheumatoid the to following biopsy arthritis, excellent do provide comparing we so. our are begun and into RA, in trial will enrollment with Phase or updates have in FDA. We
hard and investigators relationships through works team are and here and in across is the the working and advance growing with institutions associated the extremely various and this united are company and the individuals. maintaining proud with imaging The very and be Board I’m with to well-known forward. efficiently outstanding of we therapeutics Senior the moving property. applications of diligently globe group Directors, management continue closely collaborative We intellectual to company’s
there As we’ve recent said the things are in behind the working many past on we are scenes.
provide as will soon able we as updates you with as are and appropriate. We
indications therapy; patients response low alpha level new of of The moderate more our and I titled response So now rheumatoid localization progress on prediction alpha a to who alpha imaging going Phase early I’d the for into in identify severe We early technetium provide patients begin to with program. updates. we’re one, treatment XXm of trial anti-TNF are: have less will some enrolled in two, X respond anti-TNF and prediction initiated for to therapy. RA. therapy tilmanocept detail like with likely RA clinical to to of anti-TNF first-time RA our or RA an around arthritis active are evaluation with
Recall of therapies of for almost defined predict their work anti-TNF own, is to would on strong the tool bring have anti-TNF therapy of drug a Phase study the completed therapies, gold if that because there anti-TNF a uptake with use side discussed early treated. consequences being drug unlikely previously, high its not not is in reliable, be tilmanocept a ineffective was result rheumatologists out whether subtype effects. not of a group a for unnecessary disease for with a from large alone to cost, possible get-go, can subset predictor that an treatment is costs we patient with represent patient’s And previously them from worsening scan our side long-term to that RA the this along of level a alpha clinical is As ability rule lead therapies Xb to therapy particular therapy is working, need a in a the in that rate to patients working or on there baseline those the even their powerful inflammation low scan, treatment of to In with can to standard likely alphas tilmanocept most a for without be point This early can value from RA, healthy in tilmanocept patients, highly joints who to suffering effect alpha an anti-TNF non-responders scan Analysis and time far who and imaging initial RA. baseline at that single anti-TNF predictive and high alpha study accuracy provide in therapy non-response of fibroid by prediction using of are patients active RA-involved for demonstrated therapy, prediction alpha and this that with could with effects high these a the be an in provide the of of particular second-line assessment. the and efficacy otherwise of a early define is and commonly class quantitative imaging avoiding patients. disease demonstrated possible controls an prescribed that imaging case. exhibit robust those RA that in joints entire possible able can unmet XX% reproducible
support with the predictive combination of the capacity to continue So subjects, we saw in in our rest data hypothesis. the the
up in for results from upcoming trial meeting. for plan an full preparing we the submit this to medical are We And publication write dataset a course, of from international presentation journal. at the to these
sent As Phase constructive and We the analysis the After after we our X. back formal Phase make alignment, upon initiated the and back in remained with those we reviewed and Phase receipt X end of a design FDA to finalized had minutes the plan agreed Xb comment. the the FDA previously, September, modifications we meeting and protocol also of Phase X in Phase we sure the meeting data B where for meeting plan. we with to Type proposed discussed X have that statistical then
of restructured trial the not FDA, several feedback protocol reorganized additional while we did the Following itself change. from and objectives the trial
revisited As this earlier reduce restructuring, we’re range We part we enrollment. patients XXX to for from objectives the to patients. to up trial and targets trial of the open XXX an to down able achieving the of XXX trial the then XXX size to
X As operations. design sites Xb of well have Phase were are study this opened sites this These Phase moment, are another process. X in up in and the we involved the that trial and for with acquainted with
the predict these us Phase This to ability normative joints study non-RA start our set what in RA, on Xb an to the discriminate the study, to of database healthy part normative of from And tilmanocept joints is discriminate add improved data response. completed also have quantitatively. control have to of that of healthy treatment is use knowledge the to arms of inflamed with for inflamed completed should look current using positive impact a to we’re from have joints enrollment those We into do called We should the the a control inflammation and ability parameters. integral this enable RA-involved database. from not one what the like size to to accuracy our healthy NAVX-XX establish RA joints
as the both like this tilmanocept with product many joint as the essential as So parameters of competition. possible data serve in and analysis X entry the will database barriers what part play Phase well will normative one establishing to a looks of commercial an normal for
with study, in Xb patients recruitment. we signal establish are Our NAVX-XX imaging biopsy correlation of In and RA. X subtypes this results the active macrophages tilmanocept with our to each of tilmanocept Phase of from aim is imaging these joints. RA of study patients comparison imaging to recruit pathology active obtain number imaging to We histopathology and the to and order joints in in joint between comparing the patients’ of to the comparative density
call, XX subjects X As with subjects that is so minimum who screening. completed have X The have we and both enroll of an trial subtypes to of subjects designed in imaging biopsy we the each of X of in RA. a X additional this
So, size between and expected XX to overall is trial range XX.
well. recruitment terms of are we In this doing quite into trial,
UK in across the of he was patients that leader up X.X biopsy that, XX a if approached estimate enrollment guidepost his our to we sites. were and sites, RA, As could expert for of with when of tissue or world biopsy site overall joints open the month synovial first achieve per all we able subjects those
indications initial do a done Remember, readout it of as mentioned well relationships RA not that earlier, RA. critical related use with about for have this to information is qualification gold X is the open. biology in with for our CDXXX with new believe and well order sure just this we that and also very as our engage in motivated approval have their standard and required excellent RA primary is of we RA achieve in as make therapeutics. biomarker its investigators to we’re pharma How for I going pick for, carefully very will FDA It trials we provide as a rheumatologists are and know with we but sites of only We fundamental to what the we sites staff. trial that as in patient’s imaging
of this therefore of a could if can example, directly tilmanocept determine to could This from For the RA, demonstrate RA what on patients, have of impact approved. class might patient. this would study on therapeutics work significant might implications not or that and that for imaging have used results be subtype patient particular management
will benefits for on to which product. make good automating as quantification continue progress significant very the have the We well, commercial image
installed large to is be research commercial privately provide held have on transfer U.S. scale image for to and applications large quantitative partner is They reads believe We an the well intent imaging its as the at the with a tilmanocept in for letter is centers, the imaging MIM intent of reproduce have in Software in as hospitals, company’s fully companies. RA. to in for partner to with organizations ours product. as the medicine acknowledgment our signed specialty our MIM This working in and analysis clinics, They have product. robustly and nuclear imaging from leading that ability the be company important It tilmanocept medicine of data company study space. The trials, using partner. a while, of will software well. they application based for to Cleveland have pharmaceutical right a a commercial medical than that that This pilot the reads quantification for a is company, completed footprint nuclear facilities rollout products letter we a a proprietary image of software our of their imaging and quantitative half MIM perform We’ve cloud-based using this sells to more globally been can imaging means algorithm. a of rapidly redistribution commitment is can develop image RA commercial automated critical demonstrating for of analysis, reproducibly their through and automated use image RA. large-scale the the
with work the over to them finalize terms will next partnership. We several of the months
agents with has the terms The On plaque on promising for Mass line we on Manocept Preclinical at pilot sites preclinical researchers like at work of studies significant investigator-initiated of imaging imaging to General includes in PET evaluating plaque in Gallium this of co-published February. through at and tilmanocept the at Boston. mouse to completed XX international in through study XX mouse NIH-funded of have The presented MGH there analysis Gallium collaboration abstract was have them cardiovascular Gallium or reported model studies in Data for what imaging in at with localization next-generation of shows imaging Alabama agent with atherosclerotic extramural a the related of atherosclerotic Birmingham been completion University an Hospital tilmanocept in disease our progressed plaques and data study has Progress and are of previously. in model. front, imaging an new tilmanocept conference group similar the work agents internal Navidea UAB. and significantly tilmanocept atherosclerosis. tilmanocept various in uptake
with These mouse a completed set model studies of technologies important in at evaluated studies preclinical recently cancer. X imaging imaging collaborators our new UAB. of were Another
simultaneously successful, significantly localization increase for of agent at The block localization like to administered help a tilmanocept while first these liver, were from manuscript to been tilmanocept new showing our localization UAB, that we intravenous off-target agent is dramatically technology tissues to of to imaging is while studies to colleagues a liver. the highly publication. to localization target With agent results tumors major the can imaging has designed localization blocking describing site second is a designed injection. by imaging prepared off-target when the These increase technology
following patent the submit weeks property it will in by We for review few counsel. our intellectual publication next
the illuminates studies importantly, a expands of to next-generation and the constructs a have delivery our variety studies leading more constructs. doxorubicin. imaging effective dexamethasone a path greatly know-how success on success of points been as that delivery to new to therapeutic pathway Building agent. drug imaging imaging of that this So a synthesis also these payloads carry of Perhaps imaging potentially drug information, include synthesized these and
alone to mouse carrying new of reduced model. of been In the other payload addition, drug different evaluated in these another synthesized have in in macrophages. a broad-reaching therapeutic first construct macrophage be that construct altering drug, construct caring more with evaluation constructs of This tumor in construct doxorubicin in rather than in may effective a cancer of and payloads carrying showed a assay and progressed constructs or will inflammation autoimmunity, new administered tumor cancer. diseases mouse new system doxorubicin of a human rate also evaluated the construct when model. model have payload having inflammation combination for carry The could be dexamethasone but X in have significantly that applications than metabolism. that that new second the Navidea’s immune status beneficially with been growth Results a
completed, As when results are these be will and preclinical you studies and presented. announce will where we update
and And robust therapeutic forward. is our so pipeline moving
we has department time in our week a the us organization’s processing. moving weren’t administrative news India but most progress replies towards Lymphoaim, is were accepted the that reviewer are has that able recent approval. of inquiries, On file to further line, the Lymphoseek’s their moved and regulatory the last this things been senior to promising to informed approval give as They for
two On we submitted new have the intellectual applications. property provisional front,
have platform, our off-target pipeline relates for competitive related methods Manocept to applications. of first target to important the new and blocking. The maximizing is attaching second to chemotherapeutics These and uptake tissue implications
IP good also recently an work a IP sure the to meeting, certain in we together meeting as lead the North held was make and we they very strategy This rest will on and America closely world. in aligned We of Cardinal with Health prosecution going of forward. patents are we
in IP history. quarter pipeline, of X with therapeutic I both at next-generation molecules items indications. We active company’s an above other history since rights Those last And based have on that license I State we provide years this well on team current with of company’s recently diagnostic has IP support arthritis for agents the the to push trial current believe plus with strategy indications. the agreement as was Phase to X here biopsy have the protection diagnostic provisionals just that and the most while these this been and our the that arrived years Ohio to as and signing X our the productive in disease arguably to I progress new wanted the we IP will recently, the wise. filed ideas focused update. Phase largely from other the on needed therapeutic and some on and back highlights our are the the rheumatoid and continue We touch of protections the the specifically looking imaging for and we remain Xb
that, to Erika, And team for As it our things Erika of thank and the academic of financial over will always, work. trial their I’ll call and stop for network with collaborators tireless away. the updates. sites research I I their all want keep here efforts to to take for hard and clinical turn moving
